{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-132524","form_type":"8-K","ticker":"AKTS","cik":"0002035832","company_name":"Aktis Oncology, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.081606+00:00","generated_at":"2026-05-15T08:28:12.008549+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aktis Oncology: FDA clears IND for AKY-2519; full-year 2025 net loss widens to $63.7M","bullets":["FDA cleared IND for AKY-2519 (B7-H3 miniprotein radioconjugate); Phase 1b trial for solid tumors expected mid-2026.","AKY-1189 (Nectin-4) granted Fast Track designation for urothelial cancer in Feb 2026; Phase 1b enrolling.","Pro forma cash of $562.1M (incl. $335.3M net from Jan 2026 IPO) expected to fund operations into 2029.","FY2025 net loss $63.7M vs $44.0M; R&D spend $67.5M (+65% YoY) driven by clinical advancement.","Collaboration revenue from Eli Lilly partnership totaled $6.5M in FY2025, up from $1.5M in FY2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-132524","json":"https://secwatch.observer/filing/0001193125-26-132524.json","markdown":"https://secwatch.observer/filing/0001193125-26-132524.md","text":"https://secwatch.observer/filing/0001193125-26-132524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526132524/0001193125-26-132524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526132524/ck0002035832-20260330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:28:12.008549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"524331f2bdeb085a57edb5cfab50a1760ec53f2d","claim":"Aktis Oncology, Inc. reported the year ended December 31, 2025 results: revenue $6.5 million.","evidence_excerpt":"the January 2026 IPO. The Company believes that the pro forma as adjusted cash position will fund its operations into 2029. • Collaboration revenue: Collaboration revenue was $6.5 million for the year ended December 31, 2025, compared to $1.5 million for the year ended December 31, 2024. The increase was attributable to revenue recognized under the Company’s","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526132524/0001193125-26-132524-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$6.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}